The Substance Use Disorders working group of the Psychiatric Genomics Consortium (PGC-SUD14) collected individual genotypic data from 14 case/control studies and 9 family-based studies and summary statistics from GWAS of AD from 5 additional cohorts (Table 1). AD was defined as meeting criteria for a DSM-IV2 (or, for one cohort, DSM-IIIR50; a very similar construct; Supplementary Note B1) diagnosis of AD. Diagnoses were derived either from clinician ratings or semi-structured interviews. Excepting three cohorts with population-based controls (N=7,015), all controls were screened for AD. Individuals with no history of drinking alcohol and those meeting criteria for DSM-IV alcohol abuse were excluded as controls where possible (Supplementary Information A1; Life Sciences Reporting Summary). This study was approved by the institutional review board (IRB) of Washington University in St. Louis and was conducted in accordance with all relevant ethical regulations. Each contributing cohort obtained informed consent from their participants and received ethics approvals of their study protocols from their respective review boards in accordance with applicable regulations.
